GlassScriptPhysician profile
Dina Levkova
NPI 1487264008
$7,273.36
in general payments reported to CMS, 2019-2025
41 companies · $4,223 in 2025
The $4,223 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2023: $120 · 2024: $2,563 · 2025: $4,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,703 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,702.69 |
| Education | $203.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,124.83 | 2024-2025 | |
| Madrigal Pharmaceuticals | $1,079.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Intra-Sana Laboratories | $730.20 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ardelyx, INC. | $623.91 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $556.64 | 2023-2025 | Tremfya, Darzalex, Erleada |
| Pharmacosmos Therapeutics INC. | $325.59 | 2021-2024 | Monoferric, Cosela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.93 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $152.39 | 2021-2024 | Zejula, Jemperli |
| Gilead Sciences, INC. | $150.63 | 2024 | Livdelzi |
| Shield Therapeutics INC | $122.80 | 2024-2025 | |
| Novo Nordisk INC | $118.42 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $91.90 | 2024-2025 | Opdivo, Opdualag |
| Incyte Corporation | $74.14 | 2024 | Jakafi |
| Qol Medical, LLC | $71.93 | 2024-2025 | Sucraid, Sucraid |
| Biogen, INC. | $68.21 | 2025 | Leqembi |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Levkova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.